BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jordan SC, Vo AA. Donor-specific antibodies in allograft recipients: etiology, impact and therapeutic approaches. Curr Opin Organ Transplant. 2014;19:591-597. [PMID: 25304815 DOI: 10.1097/mot.0000000000000128] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wee YM, Jung JH, Kim YH, Choi MY, Kim YH, Choi DS, Cho MH, Han DJ. Involvement of indirectly allostimulated CD4+CD43highCD45RO+ T cell proliferation in the development of chronic allograft nephropathy. Exp Biol Med (Maywood) 2016;241:1217-28. [PMID: 26350952 DOI: 10.1177/1535370215601522] [Reference Citation Analysis]
2 de Sousa MV, Gonçalez AC, Zollner RL, Mazzali M. Effect of Preformed or De Novo Anti-HLA Antibodies on Function and Graft Survival in Kidney Transplant Recipients. Ann Transplant 2018;23:457-66. [PMID: 29976918 DOI: 10.12659/AOT.908491] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Wu GS. Updates on antibody-mediated rejection in intestinal transplantation. World J Transplant 2016; 6(3): 564-572 [PMID: 27683635 DOI: 10.5500/wjt.v6.i3.564] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pierson RN, Bromberg JS. Alloantibodies and Allograft Arteriosclerosis: Accelerated Adversity Ahead? Circ Res. 2015;117:398-400. [PMID: 26271536 DOI: 10.1161/circresaha.115.307065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Willuweit K, Frey A, Bieniek L, Heinold A, Büchter M, Horn PA, Wedemeyer H, Herzer K. HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level. BMC Gastroenterol 2020;20:288. [PMID: 32854625 DOI: 10.1186/s12876-020-01427-4] [Reference Citation Analysis]
6 Pilon C, Bigot J, Grondin C, Thiolat A, Lang P, Cohen JL, Grimbert P, Matignon M. Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients. Front Immunol 2020;11:34. [PMID: 32038663 DOI: 10.3389/fimmu.2020.00034] [Reference Citation Analysis]
7 Engels EA, Jennings LW, Everly MJ, Landgren O, Murata K, Yanik EL, Pfeiffer RM, Onaca N, Klintmalm GB. Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients. Transplant Direct 2018;4:e353. [PMID: 30123826 DOI: 10.1097/TXD.0000000000000792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
8 Cruzado JM, Melilli E. Looking for the needle in the kidney transplantation haystack. Clin Kidney J 2017;10:95-6. [PMID: 28638610 DOI: 10.1093/ckj/sfw122] [Reference Citation Analysis]
9 Bath NM, Ding X, Wilson NA, Verhoven BM, Boldt BA, Sukhwal A, Reese SR, Panzer SE, Djamali A, Redfield RR 3rd. Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model. PLoS One 2019;14:e0211865. [PMID: 30735519 DOI: 10.1371/journal.pone.0211865] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
10 Bia MJ. Slow Rise in Serum Creatinine Level in a Kidney Transplant Recipient 3 Years Post-Transplant. Clin J Am Soc Nephrol 2017;12:1692-4. [PMID: 28336817 DOI: 10.2215/CJN.12691216] [Reference Citation Analysis]
11 Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol 2016;9:35. [PMID: 27071449 DOI: 10.1186/s13045-016-0265-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 9.5] [Reference Citation Analysis]
12 Young JS, Chen J, Miller ML, Vu V, Tian C, Moon JJ, Alegre ML, Sciammas R, Chong AS. Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection. Am J Transplant 2016;16:2312-23. [PMID: 26928966 DOI: 10.1111/ajt.13761] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
13 Matignon M, Pilon C, Commereuc M, Grondin C, Leibler C, Kofman T, Audard V, Cohen J, Canoui-Poitrine F, Grimbert P. Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study. PLoS One 2017;12:e0178572. [PMID: 28654684 DOI: 10.1371/journal.pone.0178572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
14 Wilson NA, Bath NM, Verhoven BM, Ding X, Boldt BA, Sukhwal A, Zhong W, Panzer SE, Redfield RR 3rd. APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice. Transplantation 2019;103:1372-84. [PMID: 30830041 DOI: 10.1097/TP.0000000000002686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Townamchai N, Eiam-Ong S. Biomarkers in kidney transplantation: From bench to bedside. World J Nephrol 2015; 4(5): 487-491 [PMID: 26558185 DOI: 10.5527/wjn.v4.i5.487] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]